The Basic Principles Of Piceatannol 4'-O-?-D-glucopyranoside
All enrolled people who obtained a minimum of just one dose of zosuquidar or placebo in the course of induction had been monitored for that prevalence of adverse occasions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most typical adverse occasions were being associated with the period of prolonged and substantial myelosuppression as i